Today (March 24th), according to the latest announcement on the CDE website, Shenzhen Sinovac Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Sinovac Biotech, has proposed to include its independently developed human interferon α1b inhalation solution in the list of breakthrough therapy products, with the proposed indication being pediatric respiratory syncytial virus (RSV) lower respiratory tract infection (pneumonia, bronchiolitis). RSV is a highly contagious virus belonging to the Pneumovirus genus of the Paramyxoviridae family. It primarily affects infants under 6 months old, causing lower respiratory tract infections such as bronchiolitis and pneumonia, which can be life-threatening in severe cases. While RSV typically causes only cold-like upper respiratory tract symptoms in older children and adults, its threat to infants and young children should not be underestimated. Statistics show that almost all children are infected with RSV before the age of 2. Due to its large population, China has one of the highest numbers of lower respiratory tract infection cases in children caused by RSV globally, highlighting the urgent need for related clinical treatment.
As a long-standing and largely unconquered "silent killer" in the field of pediatric infections, the RSV-related drug market possesses significant development potential. According to data from PharmData, sales of RSV-related products in China's public hospitals are projected to exceed 400 million yuan by 2025, indicating substantial market expansion. Interferon (IFN) is a class of proteins with broad-spectrum antiviral, antitumor, and immunomodulatory effects, and is a key component of the body's innate immunity. Human interferon α1b inhalation solution represents another major breakthrough for Sinovac Biotech in the antiviral field. Interferon α1b binds to cell surface receptors, activating antiviral protein expression, inhibiting viral replication, and simultaneously enhancing immune cell activity to help the body clear the virus. Crucially, this drug is specifically formulated for children, using a nebulized inhalation method, allowing the active ingredient to directly reach the lesion, resulting in a faster onset of action and higher acceptance and safety among pediatric patients.
From a research and development perspective, Sinovac Biotech's human interferon α1b inhalation solution is progressing at a steady pace: clinical trials were approved by the CDE in November 2022; the first subject was enrolled in the Phase III clinical trial in March 2024; clinical trials were approved by the US FDA in early 2025, becoming one of Sinovac's key products submitted for dual US and Chinese applications; it was first included in the Breakthrough Therapy List in September 2025, and today it was again announced by the CDE as a proposed Breakthrough Therapy product. This proposed inclusion of human interferon α1b inhalation solution in the Breakthrough Therapy list means that it will receive priority support in subsequent research and development and review and approval processes, significantly accelerating its market launch. As a pediatric drug specifically designed to address RSV lower respiratory tract infections in infants and young children, the accelerated launch of this product will provide a new option for the treatment of RSV infections in infants and young children in China, while also helping Sinovac Biotech further solidify its core competitiveness in antiviral drug research and development, safeguarding the respiratory health of children worldwide.

https://news.yaozh.com/archive/47583.html